A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM

Must have received: surgery

Prior surgery

Must have received: radiation therapy

treatment with combination of radiotherapy and chemotherapy ± Tumor Treating Fields (Optune®)

Must have received: chemotherapy

treatment with combination of radiotherapy and chemotherapy ± Tumor Treating Fields (Optune®)

Cannot have received: cranial radiotherapy

Exception: no more than 1 course of prior cranial radiotherapy (EBRT)

Have received more than 1 course of prior cranial radiotherapy (EBRT)

Cannot have received: radiosurgery

Have received radiosurgery

Cannot have received: brachytherapy

Have received...brachytherapy

Cannot have received: hypofractionated radiotherapy

Have received...hypofractionated radiotherapy

Cannot have received: systemic therapy

Exception: no more than 2 systemic treatment protocols (lines of treatment), not including maintenance temozolomide

Have received more than 2 systemic treatment protocols (lines of treatment), not including maintenance temozolomide

Cannot have received: intra-arterial cerebral infusion therapy

Have received prior intra-arterial cerebral infusion therapy

Cannot have received: surgery

Exception: no more than 2 surgical GBM-related procedures

Have received more than 2 surgical GBM-related procedures

Cannot have received: thoracic radiation therapy

Have received prior thoracic radiation therapy